Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Bioavailability of BI 1467335 in Healthy Males
NCT03483506Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PXS-4728A in Nonalcoholic steatohepatitis (NASH) and diabetic retinopathy (DR), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve Extrapolated to Infinity at Day 28 and Maximum Measured Concentration at Day 28. Started Apr 2018; status: completed.
02
Drugs
PXS-4728A
03
Conditions
Nonalcoholic steatohepatitis (NASH)diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03483506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483506.